Ultra-rapid rollout vaccination with BNT162b2 to reduce SARS-CoV-2 infections in the general population.
Health sciences
Immunology
Population
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
18 Nov 2022
18 Nov 2022
Historique:
received:
15
03
2022
revised:
30
08
2022
accepted:
12
10
2022
pubmed:
15
11
2022
medline:
15
11
2022
entrez:
14
11
2022
Statut:
ppublish
Résumé
This study aimed to determine the impact of ultra-rapid rollout vaccination on incidence of SARS-CoV-2 infection. Vaccination with BNT162b2 was provided to 66.9% of eligible residents of the Schwaz district in Tyrol, Austria, within six days per dose (first dose: 11-16 March 2021, second dose: 8-13 April 2021). Of 11,955 individuals enrolled at nine vaccination centers (median age 44.6 years; 51.3% female), 71 had incident SARS-CoV-2 over a six-month follow-up. Incidence rates per 100,000 person-weeks were 92.3 (95% confidence interval [CI]: 70.8-120.2) at weeks 1-5 and 6.4 (3.9-10.4) at ≥6 weeks after dose 1. In these two periods, effectiveness of the vaccination campaign to reduce incident SARS-CoV-2 was 58.6% (50.8%-65.2%) and 91.1% (89.6%-92.3%) in study participants and 28.3% (23.1%-33.0%) and 64.0% (61.7%-66.1%) in the Schwaz district, compared with districts with slower vaccination rollout. Therefore, the vaccination campaign in the Schwaz district illustrates the impact of accelerated vaccination rollout in controlling the pandemic.
Identifiants
pubmed: 36373097
doi: 10.1016/j.isci.2022.105380
pii: S2589-0042(22)01652-2
pmc: PMC9639213
doi:
Types de publication
Journal Article
Langues
eng
Pagination
105380Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
Prof. Lass-Flörl reports grants, personal fees and other support from Gilead Sciences, personal fees from Merck Sharp and Dohme, grants, personal fees and other support from Astellas Pharma, personal fees and other support from Basilea, personal fees and other support from Angelini, and personal fees from F2G, all outside the submitted work. Prof. Krammer reports personal fees from Pfizer, Seqirus, 3rd Rock Ventures, Avimex, and grants from Pfizer, outside the submitted work. In addition, Prof. Krammer has a patent for an NDV-based SARS-CoV-2 vaccine with royalties paid to Avimex, PATH (humanitarian license), and a patent for serological assays for SARS-CoV-2 pending to Kantaro. Prof. Willeit reports personal fees from Pfizer outside the submitted work. The other authors report no conflicts of interest.
Références
Med (N Y). 2021 Aug 13;2(8):979-992.e8
pubmed: 34223401
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
Lancet. 2021 May 1;397(10285):1646-1657
pubmed: 33901420
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Lancet. 2022 Feb 26;399(10327):814-823
pubmed: 35131043
N Engl J Med. 2021 Oct 7;385(15):1431-1433
pubmed: 34496195
N Engl J Med. 2021 Jul 29;385(5):472-474
pubmed: 33979486
Clin Infect Dis. 2021 Sep 15;73(6):e1376-e1379
pubmed: 33900384
JAMA Netw Open. 2021 Aug 2;4(8):e2122255
pubmed: 34463744
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
N Engl J Med. 2021 Jul 22;385(4):320-329
pubmed: 34192428
Nat Med. 2021 Aug;27(8):1370-1378
pubmed: 34108716
Vaccines (Basel). 2021 Oct 07;9(10):
pubmed: 34696252
Lancet Infect Dis. 2022 Mar;22(3):302-304
pubmed: 34562376
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
JAMA. 2021 Jun 22;325(24):2457-2465
pubmed: 33956048
Lancet. 2022 Mar 5;399(10328):924-944
pubmed: 35202601
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Clin Microbiol Infect. 2021 Nov;27(11):1699.e5-1699.e8
pubmed: 34265462
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Euro Surveill. 2021 Apr;26(17):
pubmed: 33928898
BMJ. 2021 Aug 20;374:n1943
pubmed: 34417165
Vaccines (Basel). 2021 Dec 16;9(12):
pubmed: 34960235
EBioMedicine. 2021 Oct;72:103574
pubmed: 34537449
EBioMedicine. 2021 Nov;73:103626
pubmed: 34688034
MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1284-1290
pubmed: 34529637
N Engl J Med. 2021 Dec 16;385(25):e90
pubmed: 34551224
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
N Engl J Med. 2022 Jan 13;386(2):116-127
pubmed: 34942067
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Nat Microbiol. 2022 Mar;7(3):379-385
pubmed: 35132198
N Engl J Med. 2021 Feb 18;384(7):e23
pubmed: 33406324